Bristol Myers - International Biopharmaceutical Industry

Current Edition

Current Features

Subsection - Neurodegenerative Diseases

From Depression to Deep-Learning: Leveraging iPSC and AI Platforms for Evidence-Based Depression Treatment

Subsection - Oncology

Essential DMPK Strategies for IND Success

Subsection - Cell and Gene Therapy

When the Gene Editing Guide is the Drug

news

Nektar, Bristol Myers drug combination fails in late-stage melanoma trial

Dive Brief: Shares in Nektar Therapeutics fell by more than half Monday morning after the San Francisco biotech company and partner Bristol Myers Squibb disclosed ...

21 March 2022 news Biotech | Bristol Myers

Continue Reading →

news

Bristol Myers returns to Immatics for a dual-targeting cancer drug

Bristol Myers' acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol Myers h...

15 December 2021 news Breyanzi | Bristol Myers

Continue Reading →

news

Bristol Myers’ top autoimmune drug prospect takes a hit in mid-stage trial

Deucravacitinib is important to Bristol Myers for several reasons. The drug is seen as a potential top-seller, leading a new class of oral drugs that could challenge...